Trials / Unknown
UnknownNCT02183272
Emergency Ketamine Treatment of Suicidal Ideation
Ketamine as an Adjunctive Treatment of Acute Suicidal Ideation in the Emergency Setting.
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- University of Cincinnati · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the current program of research will be to test whether intranasal ketamine treatment is more effective than placebo in reducing suicidal ideation in suicidal patients presenting for acute treatment in emergency department settings. Secondary objectives will test the effect of genotypic differences in the mu opioid receptor on efficacy of ketamine and the correlation of speech patterns and facial movement patterns with subjective reductions in suicidal ideation after ketamine treatment.
Detailed description
The objective of the current program of research will be to test whether intranasal ketamine treatment is more effective than placebo in reducing suicidal ideation in suicidal patients presenting for acute treatment in emergency department settings. Secondary objectives will test the effect of genotypic differences in the mu opioid receptor on efficacy of ketamine and the correlation of speech patterns and facial movement patterns with subjective reductions in suicidal ideation after ketamine treatment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Intranasal Ketamine | Ketamine in liquid form to be distributed nasally by a board-certified physician while the subject is already in the hospital for suicidal ideation. |
| DRUG | Intranasal Saline Placebo | Intranasal Saline to be distributed by a board-certified physician while the patient is already hospitalized for suicidal ideation. |
Timeline
- Start date
- 2016-08-01
- Primary completion
- 2017-11-01
- Completion
- 2018-07-01
- First posted
- 2014-07-08
- Last updated
- 2016-08-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02183272. Inclusion in this directory is not an endorsement.